Evidence map›Paper›PMID 15781584›Full record

ArticleThe Journal of experimental medicine2005

Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus.

Peter A B Wark, Sebastian L Johnston, Fabio Bucchieri, Robert Powell, Sarah Puddicombe, Vasile Laza-Stanca, Stephen T Holgate, Donna E Davies

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of experimental medicine, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 577 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
577citing papers in PubMed, 2 pooled it
30.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

577 citing papers in PubMed, 2 syntheses or guidelines pooled it, 1,230 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Lower viral loads in subjects with rhinovirus-challenged allergy despite reduced innate immunity.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2022
    Trial
  7. INEXAS: A Phase 2 Randomized Trial of On-demand Inhaled Interferon Beta-1a in Severe Asthmatics.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2021
    Trial
  8. Trial
  9. Rhinovirus-16 induced temporal interferon responses in nasal epithelium links with viral clearance and symptoms.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2019
    Trial
  10. Trial
  11. Trial
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

517 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Peter A B WarkThe Brooke Laboratories, University of Southampton, Southampton SO16 6YD, UK. p.wark@soton.ac.uk
Sebastian L Johnston
Fabio Bucchieri
Robert Powell
Sarah Puddicombe
Vasile Laza-Stanca
Stephen T Holgate
Donna E Davies
University of Southampton · GBImperial College London · GBUniversity of Palermo · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rhinoviruses are the major trigger of acute asthma exacerbations and asthmatic subjects are more susceptible to these infections. To investigate the underlying mechanisms of this increased susceptibility, we examined virus replication and innate responses to rhinovirus (RV)-16 infection of primary bronchial epithelial cells from asthmatic and healthy control subjects. Viral RNA expression and late virus release into supernatant was increased 50- and 7-fold, respectively in asthmatic cells compared with healthy controls. Virus infection induced late cell lysis in asthmatic cells but not in normal cells. Examination of the early cellular response to infection revealed impairment of virus induced caspase 3/7 activity and of apoptotic responses in the asthmatic cultures. Inhibition of apoptosis in normal cultures resulted in enhanced viral yield, comparable to that seen in infected asthmatic cultures. Examination of early innate immune responses revealed profound impairment of virus-induced interferon-beta mRNA expression in asthmatic cultures and they produced >2.5 times less interferon-beta protein. In infected asthmatic cells, exogenous interferon-beta induced apoptosis and reduced virus replication, demonstrating a causal link between deficient interferon-beta, impaired apoptosis and increased virus replication. These data suggest a novel use for type I interferons in the treatment or prevention of virus-induced asthma exacerbations.

Indexed as

Immunity, InnateAdultAntiviral AgentsApoptosisAsthmaBronchiCaspase 3Caspase 7CaspasesCells, CulturedEpithelial CellsFemaleGene Expression RegulationHumansInterferon-betaMaleAntiviral AgentsCASP3 protein, humanCASP7 protein, humanCaspase 3Caspase 7CaspasesInterferon-betaRNA, Viral

Identifiers

PMID15781584
PMCPMC2213100
OpenAlexW2112433605

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.